- LENZ Therapeutics, Inc. announced the **commercial product availability of VIZZ™ (aceclidine ophthalmic solution) 1.44%** in the United States on **September 30, 2025**.  **[1815776_0001815776-25-000062_exhibit991-93025vizzavaila.htm:0]** **[1815776_0001815776-25-000062_lenz-20250930.htm:1]** **[1815776_0001815776-25-000062_lenz-20250930.htm:2]** 
- VIZZ is the **first and only FDA-approved aceclidine-based eye drop** for the treatment of presbyopia in adults, a condition impacting approximately **128 million adults in the United States**.  **[1815776_0001815776-25-000062_exhibit991-93025vizzavaila.htm:0]** **[1815776_0001815776-25-000062_exhibit991-93025vizzavaila.htm:1]** 
- **Professional product sample distribution** has been initiated nationwide, with **commercial product shipments to consumers starting in October** and **broad availability by mid-Q4 2025**.  **[1815776_0001815776-25-000062_exhibit991-93025vizzavaila.htm:0]** **[1815776_0001815776-25-000062_lenz-20250930.htm:2]**

LENZ Therapeutics Announces Commercial Availability of VIZZ in the U.S.

- **LENZ Therapeutics** has announced the **commercial availability** of **VIZZ** (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia.  **[1815776_20250930AQ86510:0]** **[1815776_20250930AQ86510:1]** 
- Professional product samples are being distributed to Eye Care Professionals, with **commercial shipments to consumers beginning in October** and broad availability, including via retail pharmacies, expected by **mid-Q4 2025**.  **[1815776_20250930AQ86510:0]** 
- VIZZ is designed to improve near vision for up to **10 hours** and targets approximately **128 million adults** in the United States affected by presbyopia.  **[1815776_20250930AQ86510:0]** **[1815776_20250930AQ86510:1]** 
- In the CLARITY Phase 3 clinical trial, **93% of participants** achieved 20/40 or better near vision within 30 minutes.  **[1815776_20250930AQ86510:0]**

LENZ Therapeutics Announces Commercial Availability of VIZZ

- LENZ Therapeutics' eye drop, **Viz**, for presbyopia (loss of near vision), received **FDA approval in late July** 2025.  **[1815776_tx_379067_0]** 
- The company is currently launching Viz, with **samples expected in October** 2025 and a **Direct-to-Consumer (DTC) marketing campaign scheduled for Q1 2026**.  **[1815776_tx_379067_0]** **[1815776_tx_379067_1]** **[1815776_tx_379067_3]** **[1815776_tx_379067_6]**  A sales force of approximately **100 reps** is targeting **15,000 doctors**.  **[1815776_tx_379067_1]** 
- Targeting a market of **128 million** presbyopes, Viz is positioned as a "category of one," claiming to be at least **three times more efficacious** and last at least **three times longer** than competitors like VUITY, with efficacy observed up to **10 hours**.  **[1815776_tx_379067_1]** **[1815776_tx_379067_5]** 
- Viz is priced at **$79 for a one-month supply** or **$66 per pack** for a three-month supply via e-pharmacy.  **[1815776_tx_379067_3]**  LENZ anticipates a conservative refill rate of **five refills per year** and has licensed Viz in **Greater China**, **Southeast Asia**, and **Canada** for international expansion.  **[1815776_tx_379067_4]** **[1815776_tx_379067_8]**

LENZ Therapeutics (LENZ)